Last reviewed · How we verify
NCT02914327
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Phase 1 trial testing SNX-5422 plus ibrutinib in Cancer. Withdrawn.
1 July 2018
Quick facts
| Lead sponsor | Esanex Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 2 February 2017 |
| Primary completion | 1 July 2018 |
| Estimated completion | 1 July 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SNX-5422 plus ibrutinib — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
Esanex Inc. — full company profile →
Who can join
18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will result in the removal of mutated BTK from blood mononuclear cells and/or prevents or delays disease progression of subjects with CLL
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in the structures, mechanisms and targeting of molecular chaperones.
Gu J, He Y, He C, Zhang Q, et al · · 2025 · cited 30× · PMID 40069202 · DOI 10.1038/s41392-025-02166-2 -
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL, Harrington B, Truxall J, Wasmuth R, et al · · 2021 · cited 15× · PMID 33627156 · DOI 10.1186/s13045-021-01039-9 -
Heat Shock Proteins in Lymphoma Immunotherapy.
Albakova Z, Mangasarova Y, Sapozhnikov A. · · 2021 · cited 13× · PMID 33815422 · DOI 10.3389/fimmu.2021.660085
Verify or expand the search:
- PubMed search for NCT02914327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SNX-5422 plus ibrutinib
Trials testing the same drug.
- NCT02973399 — Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL · Phase 1 · terminated
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Esanex Inc. trials
Trials by the same sponsor.
- NCT02973399 — Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02914327 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Esanex Inc.
- Last refreshed: 30 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02914327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing